BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34439749)

  • 1. Epigenetic Alterations in Pancreatic Cancer Metastasis.
    Wang SS; Xu J; Ji KY; Hwang CI
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.
    Roe JS; Hwang CI; Somerville TDD; Milazzo JP; Lee EJ; Da Silva B; Maiorino L; Tiriac H; Young CM; Miyabayashi K; Filippini D; Creighton B; Burkhart RA; Buscaglia JM; Kim EJ; Grem JL; Lazenby AJ; Grunkemeyer JA; Hollingsworth MA; Grandgenett PM; Egeblad M; Park Y; Tuveson DA; Vakoc CR
    Cell; 2017 Aug; 170(5):875-888.e20. PubMed ID: 28757253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma.
    Syren P; Andersson R; Bauden M; Ansari D
    Scand J Gastroenterol; 2017; 52(6-7):668-673. PubMed ID: 28301276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions.
    Ettel M; Zhao L; Schechter S; Shi J
    Pathology; 2019 Jun; 51(4):392-398. PubMed ID: 31060750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of epigenetics in pancreatic ductal adenocarcinoma.
    Pandey S; Gupta VK; Lavania SP
    Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.
    Hosein AN; Huang H; Wang Z; Parmar K; Du W; Huang J; Maitra A; Olson E; Verma U; Brekken RA
    JCI Insight; 2019 Jul; 5(16):. PubMed ID: 31335328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma.
    Tsuda M; Fukuda A; Kawai M; Araki O; Seno H
    Cancer Sci; 2021 Feb; 112(2):490-497. PubMed ID: 33301642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
    Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma.
    Xu R; Xu Q; Huang G; Yin X; Zhu J; Peng Y; Song J
    Biomed Res Int; 2019; 2019():9379864. PubMed ID: 31956659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.
    Xue YZ; Wu TL; Wu YM; Sheng YY; Wei ZQ; Lu YF; Yu LH; Li JP; Li ZS
    Tumour Biol; 2013 Oct; 34(5):2857-61. PubMed ID: 23681804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mediators of peritoneal metastasis in pancreatic cancer.
    Avula LR; Hagerty B; Alewine C
    Cancer Metastasis Rev; 2020 Dec; 39(4):1223-1243. PubMed ID: 32780245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity.
    Khoshchehreh R; Totonchi M; Carlos Ramirez J; Torres R; Baharvand H; Aicher A; Ebrahimi M; Heeschen C
    Oncogene; 2019 Aug; 38(34):6226-6239. PubMed ID: 31308488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis.
    McDonald OG; Li X; Saunders T; Tryggvadottir R; Mentch SJ; Warmoes MO; Word AE; Carrer A; Salz TH; Natsume S; Stauffer KM; Makohon-Moore A; Zhong Y; Wu H; Wellen KE; Locasale JW; Iacobuzio-Donahue CA; Feinberg AP
    Nat Genet; 2017 Mar; 49(3):367-376. PubMed ID: 28092686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
    Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.
    Silverman BR; Shi J
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma.
    Träger MM; Dhayat SA
    Int J Cancer; 2017 Jul; 141(1):24-32. PubMed ID: 28133736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.
    McCleary-Wheeler AL; Lomberk GA; Weiss FU; Schneider G; Fabbri M; Poshusta TL; Dusetti NJ; Baumgart S; Iovanna JL; Ellenrieder V; Urrutia R; Fernandez-Zapico ME
    Cancer Lett; 2013 Jan; 328(2):212-21. PubMed ID: 23073473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unveiling the Molecular Landscape of Pancreatic Ductal Adenocarcinoma: Insights into the Role of the COMPASS-like Complex.
    Jamali M; Barar E; Shi J
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma.
    Lu XX; Zhang SM; Fang Y; Wang ZT; Xie JJ; Zhan Q; Deng XX; Chen H; Jin JB; Peng CH; Li HW; Shen BY
    Tumour Biol; 2013 Dec; 34(6):3339-43. PubMed ID: 23749490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and epigenetics of pancreatic cancer stem cells.
    Perusina Lanfranca M; Thompson JK; Bednar F; Halbrook C; Lyssiotis C; Levi B; Frankel TL
    Semin Cancer Biol; 2019 Aug; 57():19-26. PubMed ID: 30273655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.